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Clinical/Scientific Notes
Statin-associated exacerbation of
myasthenia gravis
Michael S. Cartwright, MD; Douglas R. Jeffery, MD, PhD;
Geoffrey R. Nuss, BA; and Peter D. Donofrio, MD
Myasthenia gravis (MG) can be exacerbated by a variety of medi-
cations, which increase weakness by interrupting neuromuscular
junction transmission. Statins, which lower lipids by inhibiting
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase,
are not commonly known to worsen MG or have activity against
the neuromuscular junction.1 One report suggested that statin
therapy produced ocular myasthenia.2 However, based on the case
description, it is not clear that this patient had MG.3 We present a
patient with well-documented MG who experienced worsening of
his condition after taking different statins on four separate
occasions.
Case report. A 55-year-old man with hyperlipidemia and bor-
derline hypertension was evaluated for a 1-year history of inter-
mittent dysarthria. He first noticed dysarthria ~1 week after the
initiation of atorvastatin. At that time, MRI and blood work re-
vealed no evidence of a stroke or elevation in his creatine kinase
(CK) level. He stopped atorvastatin, and within 1 week the dysar-
thria resolved. During the next 8 months, he tried three other
statins (lovastatin, pravastatin, and simvastatin). With each sta-
tin, the dysarthria returned in ~1 week and resolved after stop-
ping the medication. There was no elevation in his CK after the
use of any of the statins. When he sought treatment in our medi-
cal center, he had experienced several weeks of dysarthria despite
avoiding statin therapy for the previous 4 months. The dysarthria
was worse in the evening and after prolonged periods of talking.
On examination, he was markedly dysarthric. He had normal
tongue movements and was not hypophonic. No cranial nerve
abnormalities or proximal muscle weakness was detected. Repeti-
tive nerve stimulation abnormalities were consistent with MG.
The facial nerve showed a 50% decrement at baseline and 50%
decrement at 30, 60, 120, and 180 seconds postexercise. The ulnar
nerve showed a 6 to 7% decrement, and the spinal accessory nerve
showed a 10 to 12% decrement postexercise. His acetylcholine
receptor antibody level was 7.5 nmol/L (normal, 0.4 nmol/L).
EMG did not reveal a myopathy, and CT of the chest did not show
a thymoma. He was started on pyridostigmine (60 mg TID) and
experienced rapid improvement in his speech.
Discussion. To our knowledge, the only report in the litera-
ture associating statin use with worsening myasthenic symptoms
involved a patient who developed ocular and systemic weakness
on four separate occasions: three times with statins and once with
a fibrate.2 However, it is not clear that this patient had MG
because no laboratory testing verified the diagnosis.3 Our patient’s
history, repetitive nerve stimulation results, acetylcholine recep-
tor antibody levels, and response to pyridostigmine substantiate
the diagnosis of MG. It appears likely that statin use exacerbated
his symptoms, given that dysarthria occurred on four separate
occasions after four different statins, and each time he improved
after discontinuation of the medication.
Medications that exacerbate MG are thought to interrupt
transmission in the neuromuscular junction. Statins, which block
HMG-CoA reductase, are not known to interfere with neuromus-
cular junction transmission,1 but we propose three ways that
statins could potentially worsen MG. First, it is now understood
that statins have immunomodulatory properties, including the
ability to induce production of the Th2 cytokines interleukin
(IL)-4, IL-5, and IL-10.4 Animal and human studies suggest that
these Th2 cytokines play a role in the development of MG;5 there-
fore, it is possible that by up-regulating Th2 cytokine production,
statins could lead to worsening MG.
Second, statins have been postulated to cause mitochondrial dys-
function by depleting endogenous coenzyme Q10.6 The presynaptic
nerve ending and the postsynaptic junction are rich in mitochondria.
For this reason, statin-induced mitochondrial dysfunction could in-
terrupt transmission in the neuromuscular junction and worsen MG.
A third theory is that a statin myopathy could exacerbate the
underlying weakness of MG. Myopathy is a well-described side
effect of statins, and it ranges from mild without CK elevation to
overt rhabdomyolysis. It is possible that in addition to having MG,
the patient described in our case also experienced a statin myop-
athy. This dual-hit hypothesis may explain why the association
between statin use and exacerbation of MG has not been exten-
sively documented.
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The fragile X premutation presenting as
postprandial hypotension
P. Pugliese, MD; G. Annesi, PhD; N. Cutuli, MD; G. Arabia, MD;
G. Nicoletti, MD; F. Annesi, PhD; P. Tarantino, PhD;
A. Gambardella, MD; P. Valentino, MD; M. Zappia, MD;
and A. Quattrone, MD
The fragile X-associated tremor/ataxia syndrome (FXTAS) is a
neurodegenerative disorder consisting of progressive intention
tremor and cerebellar ataxia recently described in men with the
premutation (55 to 200 CGG repeats) in the promoter region of the
fragile X mental retardation 1 (FMR1) gene1 and with grandchil-
dren with fragile X syndrome (FXS).2 We describe here a patient
with postprandial hypotension and intention tremor carrying an
FMR1 premutation allele and without a family history for FXS.
Case report. A 73-year-old man was referred to our clinic for
episodes of blurred vision, dizziness, and weakness appearing af-
ter meals and associated with low blood pressure (BP) values.
These episodes began 1 year before our visit, but the patient also
had bilateral hand tremor with onset at age 71 years, mostly
pronounced with posture and action. His family history was unre-
markable for peculiar neurologic disorders: he had two healthy
sons aged 42 and 39 years and two healthy grandchildren. More-
over, he had only two sisters: one died at age 38 years during
delivery, and the other died at age 80 years from bronchopneumo-
nia and had healthy children and grandchildren (two males and
one female). Neurologic examination revealed facial hypomimia
and mild asymmetric (left greater than right) postural tremor in
the distal upper extremities, which increased by action (without
resting tremor). Tone, strength, sensation, deep tendon reflexes,
and plantar responses were normal. There was no ataxia, and
stance and gait were normal, including tandem gait. A general
cognitive screen was normal (Mini-Mental State Examination
score, 25/30), but specific memory problems or executive function
deficits could not be excluded because a more complete neuropsy-
chological testing was not done. EEG, EMG, and nerve conduction
studies were normal, as was sympathetic skin response recorded
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from the hands after median nerve stimulation. Brain MRI re-
vealed only moderate cortical atrophy without any signs of white
matter disease. General physical examination was normal, with-
out sexual or urinary disturbances, except for mild orthostatic
hypotension with a decrease in systolic BP of 20 mm Hg when
changing from a lying to a standing position. Moreover, a 24-hour
BP profile (figure) showed a reversed circadian BP rhythm with
higher nighttime than daytime values and after each meal a de-
crease of systolic BP ranging 40 to 65 mm Hg without a compen-
satory increase in heart rate: these changes of systolic BP were
associated with dizziness and blurred vision, lasting a couple
hours after meals and were interpreted as postprandial hypoten-
sion. Cardiovascular examinations, including EKG with trans-
esophageal stimulation and study of R-R interval variability
during deep breathing, echocardiography, and Doppler ultrasound
studies of the carotid and vertebrobasilar systems, were otherwise
normal. The administration of midodrine (2.5 mg TID) decreased
postprandial symptoms. The molecular analysis of FMR1 gene
revealed a premutation carrier status with 73 CGG repeats.
Discussion. The clinical presentation of this patient, who had
severe postprandial hypotension associated with mild postural
and intention tremor and who was carrying an FMR1 premuta-
tion, is atypical for FXTAS. Cases of FXTAS described thus far
have consisted of intention tremor and/or ataxia, variously associ-
ated with cognitive decline, peripheral neuropathy, parkinsonism,
and autonomic dysfunction;1,3,4 moreover, MRI showed generalized
brain atrophy and/or T2 hyperintensities of the middle cerebellar
peduncles,3 although the absence of this sign is not unusual, being
present in only 59% of patients with FXTAS.5 Most important, all
the reported cases of FXTAS were identified from families with
known cases of FXS.2 Nevertheless in our patient, even if a family
history for FXS was absent, a clinical diagnosis of “possible” FX-
TAS could be made because, in addition to the mandatory crite-
rion of the FMR1 premutation status, he had intention tremor
(one clinical major criterion) and moderate brain atrophy (one
radiologic minor criterion).3 However, his main disturbances were
postprandial symptoms caused by decreases in BP after meals;
moreover, he had a reversed circadian BP rhythm and a mild
orthostatic hypotension. This autonomic profile, although nonspe-
cific, could identify an autonomic impairment, such as the dys-
function occurring in atypical Parkinson disease or multiple
system atrophy.6 This autonomic dysfunction has not been previ-
ously described in patients with FXTAS, in whom dysautonomia
has been mainly reported as impotence, hypertension, or bladder
dysfunction.1,3
There is growing evidence that the clinical phenotypes of FX-
TAS may be more heterogeneous than previously thought. FMR1
premutations have been reported in patients with essential trem-
or4 and in cases of sporadic ataxia without a family history for
FXS.7 Our report adds further evidence to the clinical spectrum of
FXTAS and suggests that DNA testing for the FMR1 premutation
may reveal additional carriers among patients with BP dysauto-
nomia. Nevertheless, further studies on more FMR1 premutation
carriers are needed to confirm whether BP dysautonomia is a
clinical feature of these subjects.
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Heterozygous Niemann–Pick disease type C
presenting with tremor
Keith A. Josephs, MST, MD; Joseph Y. Matsumoto, MD;
and Noralane M. Lindor, MD
Tremor is defined as rhythmic oscillation of a body part. The
differential diagnosis of tremor is extensive; however, when there
is a family history of tremor, the diagnosis most likely will be
essential tremor. We describe a woman who sought treatment for
tremor, had a family history of tremor, and was found to have a
unique diagnosis.
Case report. A 75-year-old woman was referred to the neurol-
ogy department with a 10-year history of tremor, initially a side-
to-side head tremor. Five years after onset, her tremor had
progressed, involving her right hand and 1 year later, the left. The
tremor in her upper extremities predominantly occurred at rest;
however, she also stated that occasionally she would experience a
tremor in her hands while holding a cup of coffee or a deck of
cards. She carried a diagnosis of Parkinson disease, but her
tremor did not improve with 1,000 mg of L-dopa/carbidopa ther-
apy, which she took for 3 months. Her family history was interest-
ing because three brothers all developed tremor and an incurable
neurologic disease.1 Her neurologic inventory was otherwise
negative.
On examination, she was jocular. On the Short Test of Mental
Status, she received a score of 31 of 38.2 Her cranial nerve exami-
nation was normal. She had a continuous “no-no” head tremor and
mild lip and voice tremor. With mental activation, she developed a
severe tremor in her upper extremities, worse on the right. With
her arms held outstretched, she had a mild tremor. When her
limbs were in a position of partial repose (e.g., with her left elbow
on the armchair and her hand on her lips), she developed a severe
tremor. Her gait was unremarkable, except for a moderate over-
flow tremor of both upper extremities. Her medical examination,
including abdominal examination, was unremarkable. A complete
Figure. A 24-hour noninvasive ambulatory recording of
blood pressure and heart rate. Systolic blood pressure val-
ues are on the top (continuous line); diastolic blood pres-
sure values are in the middle (dashed line); and heart rate
values are on the bottom (dotted line).
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blood count was normal, except for the platelet count, which was
93  109/L (normal, 150 to 450  109/L). Peripheral blood smear
revealed normal platelet morphology but clumping. Her thyroid
and liver function studies, serum ceruloplasmin, and 24-hour
urine copper collection were normal. A lactic acid level was ele-
vated at 2.0 mmol/L (normal, 0.93 to 1.65 mmol/L). An abdominal
ultrasound revealed diffuse fatty infiltrate of the liver and normal
spleen size. MRI head scan revealed patchy increased T2 signal
changes in the white matter of both cerebral hemispheres consis-
tent with chronic small vessel ischemic changes.
A multichannel EMG recording initially revealed no resting
tremor and an occasional postural 5-Hz tremor in the left arm.
With mental activation, however, she developed a high amplitude
synchronous 4- to 5-Hz tremor in both hands that disappeared
immediately after the alerting procedure was discontinued. The
findings were consistent with a parkinsonian tremor.
Spinocerebellar ataxia panel, cholesterol esterification, fillipin
staining, and sphingomyelinase were normal. We reviewed the
original article on the patient’s brothers.1 Three brothers had a
childhood-onset disorder characterized by tremors, dysarthria,
gait ataxia, dementia, spasticity, and vertical supranuclear gaze
palsy (VSGP). The tremors occurred only under stressful situa-
tions and were not found on examination. Since publication of that
article, a bone marrow aspirate completed in 1981 on the youngest
brother (III-28) showed cells suggestive of sea-blue histiocytes.
Therefore, we proceeded to genetic testing for Niemann–Pick dis-
ease type C (NPC). Our patient was found to be a carrier for one
mutation within the NPC1 gene. In exon 20, there was a
2974G3C mutation changing glycine3arginine at position 992
(GGGCGG), indicating that our patient is a carrier for NPC and
supporting the clinical suspicion of NPC in her brothers.
Discussion. NPC is an autosomal recessive disease character-
ized by dementia, ataxia, VSGP, and splenomegaly.3 Adults may
have psychosis,4 but adult onset is rare. Our patient is a carrier of
one mutation of the NPC gene. Heterozygous carriers of NPC have
not been reported to have neurologic symptoms. However, the
finding of this known mutation is suggestive of the cause of our
patient’s neurologic disease.5 The absence of dementia, VSGP, and
spasticity at age 73 years is most likely because she only carries
one mutation.
In a recent review of 16 patients with adult-onset NPC,6
tremor was not found, making this patient and her family unique
in terms of presenting and progressive signs. The characteristic of
the upper extremity tremor noted in our patient is in keeping with
a parkinsonian tremor. This was the clinical suspicion that was
corroborated by multichannel EMG recording.
Heterozygous NPC may have neurologic disease and should be
considered in the differential diagnosis of patients with a parkin-
sonian tremor.
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Radicular myoclonus induced by repetitive
neck movements in a patient with cervical
spondylosis
V. Di Lazzaro, MD; A. Oliviero, MD; P. Profice, MD;
T. Tartaglione, MD; F. Pilato, MD; E. Saturno, MD;
M. Dileone, MD; and P.A. Tonali, MD
Myoclonus results from abnormal activity in many different parts
of the CNS.1 Only a few cases of peripheral nervous system-
generated myoclonus have been reported in patients with spinal
root lesion.2,3
We report a patient who developed a cervical segmental myoc-
lonus immediately after prolonged repetitive flexion-extension
neck movements.
Case report. A 67-year-old man developed neck pain and ten-
sion. In an attempt to reduce neck tension, he started to perform
repetitive flexion-extension neck movements for ~10 minutes ev-
ery morning. After a few days, he developed involuntary jerking of
the right shoulder immediately after repetitive flexion-extension
neck movements. The general practitioner, who thought that this
was a simple partial seizure, injected the patient with 2 mg diaz-
epam ~30 minutes after the onset of symptoms and again 2 hours
later, but the treatment was ineffective.
The patient arrived at our emergency department 6 hours
later. On examination, he had rhythmic, involuntary jerks of the
right shoulder on the horizontal plane and a slight lateral flexion
of the head on the right side. Neurologic examination was other-
wise normal. The involuntary activity was not affected by neck
movements or by distraction or mental concentration. Blood count
and chemistries (glucose, liver and renal function tests, electro-
lytes, and vitamin B12 level), rheumatologic screen (erythrocyte
sedimentation rate, antinuclear antibody, anti-DNA, rheumatoid
factor, complement factors C3 and C4, and anticardiolipin anti-
body), copper and ceruloplasmin concentration, and thyroid func-
tion were normal. The EEG was normal. However, during
activation with hyperventilation, the ongoing involuntary activity
increased in frequency and amplitude in the absence of EEG
modification.
EMG recording revealed cocontraction of several muscles with
synchronous repetitive discharges of motor units occurring in
trains lasting several minutes in right pectoralis major (clavicular
head), teres major, pronator teres, and intermittently in biceps
brachii and brachioradialis muscles (all supplied by the C6 root).
The involuntary activity in the neck muscles originated from a
deep muscle and was not documented with EMG, but it is conceiv-
able that it originated from the longus colli muscle that produces
lateral flexion of the head and is supplied mainly by the C6 root.
The duration of bursts of activity ranged from 350 to 410 ms.
Subsequent recordings showed two different rates of involuntary
movements, either 0.5 or 1.7 Hz. Hyperventilation either precipi-
tated the involuntary activity or increased the amplitude of ongo-
ing involuntary movements. When the frequency of involuntary
movement was 0.5 Hz, it changed to 1.7 Hz after hyperventilation.
No signs of denervation were found. The blink reflex and its recov-
ery cycle were normal. Motor evoked potentials and somatosen-
sory evoked potentials (SEPs) after stimulation of radial, median,
and ulnar nerve were normal. The recovery cycle of the spinal
SEPs evoked by pairs of stimuli to the radial nerve, which distrib-
utes to the C6 and C7 dermatomes, was normal. This test may
reveal excitability changes within the dorsal horn in segmental
myoclonus of spinal origin.4 Cervical cord MRI revealed that the
right C6 neural foramen was narrowed because of degenerative
spondylotic changes, the spinal cord being normal.
The patient stopped the morning stretching activity of neck
muscles. The movements resolved in the next 3 days.
Discussion. The segmental distribution of jerks involving C6
myotome, the MR evidence of narrowing of the right C6 neural
foramen, together with the absence of any excitability change in
cerebral cortex, brainstem, or spinal cord suggest that the jerks
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originated at the peripheral level, conceivably from the C6 root. It
is likely that the repetitive flexion-extension neck movements had
determined a transient mechanical irritation of this root. Ephaptic
transmission or ectopic excitation of the spinal root may cause the
involuntary movements in spinal root lesions.3 However, this
mechanism could not explain the sensitivity to hyperventilation of
the myoclonus and the presence of two definite frequencies. One
possibility is that it originates from retrograde impulse propaga-
tion along the relatively intact motor root consequent to the me-
chanical irritation. The abnormal activity originating from
mechanical irritation is known as back-discharge.5 A similar
mechanism has previously been proposed for segmental myoclo-
nus induced by the tip of an intrathecal catheter.6 The abnormal
retrograde activity may trigger the repetitive discharge of the
anterior horn cells of the corresponding spinal segment. The inter-
action between the ongoing activity in the segmental spinal cord
circuitry (that oscillates continuously in response to segmental
and suprasegmental inputs) and the retrograde activation would
determine the frequency and amplitude of involuntary movements
and would justify the presence of more than one pattern of invol-
untary activity. Hyperventilation could produce an increment in
the involuntary activity through the alkalosis that increases neu-
ron excitability.7
Myoclonus associated with a root lesion has been reported in
two cases that showed clinical findings similar to those of the
present patient with involuntary movements confined to muscles
supplied by a single root.2,3 In the first patient, who had a tumor
mass in the intervertebral foramen between the fourth and fifth
thoracic vertebrae, the involuntary movement disappeared after
local radiotherapy.2 The second patient, who had an L3 degenera-
tive radiculopathy, was successfully treated with valproate and
clonazepam.3
The rarity of radicular myoclonus contrasts with the high inci-
dence of radiculopathies, and it is possible that a genetic or other
factor may contribute to its development.
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Primary respiratory failure in inclusion body
myositis
N.C. Voermans, MD; M. Vaneker, MD; G.J.D. Hengstman, MD;
H.J. ter Laak, PhD; C. Zimmerman, MD; H.J Schelhaas, MD;
and M.J. Zwarts, PhD
The idiopathic inflammatory myopathies are a group of disorders
characterized by acquired muscle weakness and presence of in-
flammatory infiltrates in skeletal muscle.1,2 The three most com-
mon diseases within this group are dermatomyositis (DM),
polymyositis (PM), and inclusion body myositis (IBM). Respiratory
muscle weakness with respiratory failure is a well-recognized
complication in PM and DM but has only rarely been reported in
IBM.3,4 Symptomatic respiratory failure in IBM is considered to be
secondary to coincidental pulmonary disease.5 We report a patient
with IBM who developed subacute respiratory failure caused by
primary respiratory muscle weakness.
Case report. A 58-year-old woman sought treatment for
slowly progressive muscle weakness, dysphagia, and weight loss.
Her medical history was unremarkable, and she did not use any
myotoxic drugs. Physical examination revealed normal speech,
mild facial weakness, dysphagia without aspiration, and general-
ized muscle weakness (Medical Research Council [MRC] score, 4)
with asymmetric weakness of the forearm muscles (right, MRC 4;
left, MRC 3). Muscle atrophy was most pronounced in the quadri-
ceps muscles. Creatine kinase was mildly increased (285 U/L;
normal, 180 U/L). Nerve conduction studies were normal. EMG
demonstrated spontaneous activity and a mixed pattern of short-
duration low-amplitude and long-duration high-amplitude motor
unit potentials at submaximal voluntary contractions. By EMG,
forearm flexor muscles were more involved than forearm extensor
muscles. Muscle biopsy from the anterior tibial muscle revealed a
small number of muscle fibers surrounded by collagen, fat cells,
and inflammatory infiltrates. IBM was diagnosed according to
established criteria,6 and the patient was referred to a rehabilita-
tion clinic.
Eight months after initial presentation, she gradually devel-
oped shortness of breath on exertion. She subsequently experi-
enced morning headaches, excessive daytime sleepiness, and
confusion. One day she was found unconscious as a result of se-
vere hypercapnia and hypoxemia and required intubation and
mechanical ventilation. Arterial blood gas analysis after intuba-
tion showed elevated PCO2 (7.9 kPa  806 mm H2O) and bicarbon-
ate (33.7 mmol/L), reflecting chronic hypoventilation. Ancillary
investigations showed no signs of cardiac disease or respiratory
infection. Initially, nighttime apneas occurred lasting up to 45
seconds with hypercapnia (PCO2 8.2 kPa  836 mm H2O) and
elevated bicarbonate (34.8 mmol/L), after which mechanical venti-
lation was adjusted. Apparently, the respiratory drive in our pa-
tient was depressed during sleep. This probably resulted from
bicarbonate retention and sleep deprivation caused by frequent
arousals during REM sleep because of hypercapnia.7 Her general
condition improved, and the need for daytime ventilatory support
decreased. She underwent tracheotomy and thereafter required
volume-regulated ventilation for 2 hours in the afternoon and at
night. Two months after admission, she was discharged home on
continued mechanical ventilation.
The presence of severe respiratory failure made us reconsider
her diagnosis. Empirical treatment with prednisone (50 mg daily
for 4 weeks) resulted in minimal increase in muscle strength.
Nerve conduction studies of the phrenic nerve demonstrated low
amplitudes of the compound motor action potential of the dia-
phragm bilaterally. EMG revealed poor recruitment without spon-
taneous activity of the diaphragm and intercostal muscles. Muscle
biopsy from the tibialis anterior showed myopathic changes with
invasion of non-necrotic muscle fibers by mononuclear cellular
infiltrates, basophilic rimmed vacuoles, and sarcolemmal HLA-
ABC positivity of all muscle fibers, consistent with the diagnosis
of IBM6 (figure). Pulmonary function testing revealed mildly im-
paired vital capacity (1.87 L; normal, 2.60 L) and decreased mouth
pressures (maximal expiratory pressure, 3.01 kPa  307 mm H2O;
normal, 8.90 kPa; maximal inspiratory pressure, 1.90 kPa  193
mm H2O; normal, 6.90 kPa), reflecting an extraparenchymal re-
strictive pattern. It was concluded that the patient had IBM6 with
respiratory muscle weakness, which had resulted in primary re-
spiratory failure.
Discussion. Respiratory failure in patients with IBM is gener-
ally believed to occur only secondary to aspiration pneumonia or
coincidental pulmonary or cardiac disease.5 Primary respiratory
failure has, to the best of our knowledge, been reported only twice
in literature.3,4 One of these reported patients had a concomitant
human T-cell lymphotropic virus type 1 infection.4 In our patient,
respiratory failure resulted from hypoventilation caused by weak-
ness of the diaphragm and intercostal muscles. Our limited
awareness of this manifestation of IBM delayed its recognition
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and resulted in life-threatening respiratory failure. Only then the
ventilatory support was started, and the vicious circle of respira-
tory muscle weakness, hypoventilation, hypercapnia, sleeping
problems, deterioration of the general condition, weight loss, and
severe respiratory failure7 was broken. Moreover, we started high-
dose corticosteroid treatment, which involves a risk of serious
adverse effects. In conclusion, primary respiratory failure can oc-
cur in patients with IBM, and awareness of this potentially life-
threatening complication is warranted, especially for patients
with signs and symptoms suggestive of hypoventilation.
From the Neuromuscular Centre Nijmegen and the Departments of Neurol-
ogy (Drs. Voermans, Hengstman, ter Laak, and Schelhaas), Anesthesiology
(Dr. Vaneker), Intensive Care Medicine (Dr. Zimmerman), and Clinical Neu-
rophysiology (Dr. Zwarts), University Medical Centre Nijmegen, The
Netherlands.
Received April 21, 2004. Accepted in final form July 8, 2004.
Address correspondence and reprint requests to Dr. H.J. Schelhaas, Neuro-
muscular Centre Nijmegen, Department of Neurology, University Medical
Centre Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands;
e-mail: h.schelhaas@neuro.umcn.nl
Copyright © 2004 by AAN Enterprises, Inc.
References
1. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myosi-
tis. N Engl J Med 1991;325:1487–1498.
2. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body
myositis. Observations in 40 patients. Brain 1989;112:727–747.
3. Cohen R, Lipper S, Dantzker DR. Inclusion body myositis as a cause of
respiratory failure. Chest 1993;104:975–977.
4. Littleton ET, Man WD, Holton JL, et al. Human T cell leukaemia virus
type I associated neuromuscular disease causing respiratory failure.
J Neurol Neurosurg Psychiatry 2002;72:650–652.
5. Griggs RC, Rose MR. Evaluation of treatment for sporadic inclusion body
myositis. In: Askanas V, Serratrice G, Engel WK, eds. Inclusion-body
myositis and myopathies. Cambridge: Cambridge University Press,
1998:331–350.
6. Verschuuren JJ, Bradising UA, van Engelen BGM, van der Hoeven H,
Hoogendijk J, Wintzen AR. Inclusion body myositis. In: Emery AEH, ed.
Diagnostic criteria for neuromuscular disorders, 2nd ed. London: Royal
Society of Medicine Press, 1997:81–84.
7. Perrin C, Unterborn JN, D’Ambrosio C, Hill NS. Pulmonary complica-
tions of chronic neuromuscular disease and their management. Muscle
Nerve 2004;29:5–27.
Cerebral toxoplasmosis in a patient with
common variable immunodeficiency
Martin Holtkamp, MD; Ali Fuat Okuducu, MD;
Randolf Klingebiel, MD; and Christoph J. Ploner, MD
Cerebral toxoplasmosis is commonly seen as an opportunistic dis-
ease in patients with compromised cellular immunity.1 Thus far,
purely humoral immune defects, as seen in common variable im-
munodeficiency (CVID), have not been described to facilitate cere-
bral toxoplasmosis. Here, we present a patient with intracerebral
mass lesions caused by toxoplasmosis, which were apparently fa-
cilitated by a humoral immune defect with combined immunoglob-
ulin (Ig) A, IgG, and IgM deficiency.
Case report. A 52-year-old woman subacutely developed gait
difficulties, impaired upper limb coordination, and swallowing and
articulation difficulties. The patient had a history of CVID, which
had been substituted with 10 g Igs every month. Four weeks
before neurologic symptoms, an attack of autoimmune hemolytic
anemia was managed with prednisolone in a dosage that was
tapered from 100 to 30 mg/d.
Clinically, the patient had moderate spastic tetraparesis and
severe dysarthria and dysphagia. C-reactive protein was slightly
elevated to 1.1 mmol/L. Temperature, white blood cells, and differ-
ential hemogram revealed no abnormalities. Lymphocytic sub-
populations were normal, except for an elevation of CD19 B cells
to 0.63/nL (normal range, 0.1 to 0.4). Igs were decreased with IgA
5 mg/dL (normal range, 70 to 400), IgG 214 mg/dL (normal, 700
to 1,600), and IgM 10 mg/dL (normal, 40 to 230). The patient
tested negative for HIV-1 and -2. MRI showed bilateral hemor-
rhagic lesions in the basal ganglia with irregular contrast en-
hancement and marked perifocal edema (figure), suggestive of
either lymphoma or toxoplasmosis. CSF showed lymphocytic pleo-
cytosis with 108 leukocytes/L. Serologic and PCR examinations
in serum and CSF were negative for neurotropic viruses of the
herpes group and tuberculosis. Serologic examinations in serum
and CSF were negative for Aspergillus, Candida species, crypto-
coccus, Borrelia burgdorferi, toxoplasmosis, and Treponema palli-
dum. Molecular diagnosis for these agents was not performed.
There was no evidence of systemic lymphoma on whole body CT
scan, immunofixation, and bone marrow examination.
Initial treatment was polypragmatic with acyclovir, ceftriax-
one, and cotrimoxazole. Dexamethasone was given for marked
perifocal edema. Because diagnosis was unclear, stereotactic brain
biopsies were obtained from the left basal ganglia lesion. Histol-
ogy revealed an inflammatory reaction with necrotic areas, and
immunohistochemical staining showed pseudocysts containing
Toxoplasma gondii organisms and extracellular parasites espe-
cially in necrotic areas (see figure). Treatment with py-
rimethamine and sulfadiazine was initiated. Six and 14 weeks
after antitoxoplasmosis treatment was started, CSF cell count was
normal. The tetraparesis had resolved, and dysarthria had moder-
ately improved; however, dysphagia was still prominent. Clinical
improvement correlated with marked shrinkage of the bilateral
perifocal edema, although lesions in the basal ganglia remained
unchanged (see figure).
Discussion. In this patient, neuroimaging could not differen-
tiate between lymphoma and toxoplasmosis. Serology for toxoplas-
mosis was negative, but antibody production was limited by the
known CVID. Brain biopsy was performed and showed pseudo-
Figure. (A) Rimmed vacuole (hematoxylin-phloxine stain);
bar, 50 m. (B) Sarcolemmal HLA-ABC positivity (HLA-
ABC stain); bar, 50 m.
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cysts containing T. gondii organisms. The patient’s clinical, CSF,
and neuropathologic findings make CNS lymphoma highly un-
likely and do not allow for a diagnosis other than cerebral
toxoplasmosis.
Resistance against cerebral toxoplasmosis is mainly sustained
by interferon-–dependent, CD8 T cell–mediated immunity.1
Therefore, T. gondii affects the brain almost exclusively in pa-
tients with compromised cellular immunity.1 The patient reported
here did not have cellular immunodeficiency, but rather a defi-
ciency of IgA, IgG, and IgM causing a pronounced humoral im-
mune defect.
After exclusion of other known causes, deficiency of IgA, IgG,
and IgM, referred to as CVID, is the most frequent of the primary
specific immunodeficiencies.2 The syndrome is rare, with an inci-
dence of 1:50,000 to 1:200,000.3 Infections with unusual organisms
such as Pneumocystis carinii, mycobacteria, fungi, enteroviruses,
and Giardia lamblia are seen in few patients with CVID.2 Thus
far, cerebral toxoplasmosis has only been described in one patient
with CVID.4 However, humoral and cellular immunity was de-
pressed in this patient. From an epidemiologic point of view, coin-
cidence of cerebral toxoplasmosis and the rare condition of CVID
is unlikely to be purely accidental. Therefore, we suggest that
cerebral toxoplasmosis in this patient was facilitated by the severe
humoral immune defect, although an additional role of steroid
treatment appears possible. Complementing our findings, experi-
mental data have shown that a reduction of antibody-producing B
cells decreases the resistance of mice brains toward T. gondii. In
addition, treatment of infected mice with anti–T. gondii IgG re-
duced mortality and prolonged survival.5
In summary, we present a patient with cerebral toxoplasmosis
probably facilitated by pre-existing common variable immunodefi-
ciency. Toxoplasmosis should be considered in cases of unex-
plained intracerebral mass lesions in patients with cellular and
humoral immunodeficiencies. Conversely, in cases of unexplained
cerebral toxoplasmosis, screening for humoral immunodeficiencies
may be warranted.
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Alopecia and cutaneous atrophy after greater
occipital nerve infiltration with corticosteroid
K.G. Shields, MRCP; M.J. Levy, MRCP; and
P.J. Goadsby, MD, PhD
Greater occipital nerve (GON) infiltration is used as a treatment
for patients with primary and secondary headache disorders, in-
cluding migraine and cluster headache.1,2 This procedure has sev-
eral advantages, including ease of performance and a relative lack
of complications. As the physiology of the trigeminocervical neu-
rons is better understood3 and possible brain modulatory roles of
greater occipital nerve stimulation are explored,4 the procedure
may gain increased usage. In our experience, GON infiltration is
highly efficacious for certain patients, particularly those with ten-
derness over the nerve, and it remains a valuable intervention for
the management of headache disorders. It is generally without
side effects. Here we report two cases in which the procedure has
been complicated by a previously unreported side effect of alopecia
and cutaneous atrophy. These patients represent 2 of the last 100
patients we have injected for various headache indications.
Case reports. Case 1. A 27-year-old man sought treatment
for a history of headaches from childhood consistent with a diag-
nosis of migraine with aura. He now had chronic daily headache,
with frankly migrainous exacerbations twice weekly, and was con-
suming compound analgesic preparations daily.
On examination, he had tenderness in the region of the right
GON.
A nerve block was performed with 80 mg methylprednisolone
acetate in 2 mL and 3 mL of 2% lidocaine, resulting in anesthesia
Figure. (A) Cross-sectional MR scans at the level of the
basal ganglia. (a) Fluid-attentuated inversion recovery
(FLAIR) study showing hyperintense signals within the
basal ganglia bilaterally, predominantly on the left side,
extending into the internal capsula and thalamus. T1-
weighted unenhanced (b) and gadolinium-enhanced (c)
images at the same level as in (a). Hyperintense hemor-
rhagic lesions are depicted within the basal ganglia and
irregular contrast enhancement. (B) Neuropathologic find-
ings from the biopsy specimens of the left basal ganglia
lesion. (a) Inflammatory infiltration including histiocytes
and lymphocytes (H-E, original magnification, 400).
(b) Pseudocyst within inflammation (arrow; H-E, original
magnification, 1000). (c) Giemsa-stained slide shows
a pseudocyst (arrow; original magnification, 1000).
(d–f) Immunohistochemical staining for Toxoplasma gon-
dii. Numerous extracellular organisms are present in ne-
crotic area (d; original magnification, 400).
Inflammatory cells, an extracellular organism (arrow),
and a toxoplasma pseudocyst (e; original magnification,
400). A high-power view of this pseudocyst (f; original
magnification, 1000).
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of the right posterior aspect of the head. He subsequently enjoyed
a headache-free period lasting 3 months. The only side effect re-
ported was hair loss at the site of the injection. Three small, but
conspicuous, round patches of alopecia were noted. Each was ~1
cm in diameter and was associated with marked cutaneous atro-
phy. These patches are still present 11 months later.
Case 2. A 55-year-old woman sought treatment for a 2.5-year
history of left occipital headache that was diagnosed as migraine
without aura. A left GON infiltration was performed using the
same technique and compounds as in Case 1, which resulted in a
complete resolution of her symptoms for 4 days. No side effects
were reported. The procedure was repeated 6 months later be-
cause it had been the only intervention to afford any symptomatic
relief. Unfortunately, the benefit on the second occasion was less
than on the first. After the second injection, a small patch of
atrophy and alopecia measuring 1.5 cm in diameter was noticed
(figure). This patch was still noticeable 10 months after the injec-
tion, although it appeared to be resolving.
Discussion. We describe alopecia with underlying fat atrophy
after GON infiltration with lidocaine and depo-corticosteroids for
the management of primary headache. This is a commonly used
procedure in headache clinics, and patients and clinicians need to
be aware of this possible complication. Although corticosteroids
are not universally used during GON blockade, relief of headache
may be prolonged after their use.1 This issue now needs to be
revisited and defined for each headache type treated so the real
risk-benefit assessment can be made.
A variety of corticosteroid preparations and doses have been
used,1,2,5 but this side effect was not reported. The estimated occur-
rence of cutaneous atrophy after corticosteroid injection ranges
from 1 to 14%,6 although there may be under-reporting. It appears
to be more common in premenopausal women.7 Mixing corticoste-
roids with other solutions, such as saline or local anesthetic,
should only be done if the solutions are miscible—if solubility is
altered, it may result in a subcutaneous depot injection. Resolu-
tion of cutaneous atrophy is reported to occur after 6 to 7 months,
although it may persist up to 24 months.7
GON infiltration is undoubtedly an effective and useful treat-
ment for certain patients. At times, it may be the only interven-
tion to offer a patient symptomatic relief. There are currently no
firm guidelines concerning patient selection or clinical features
predictive of a successful outcome. There is no clear consensus on
the efficacy of the procedure itself. However, given the lack of
severe side effects associated with GON infiltration, it should still
be considered as a useful therapy for the management of head
pain. We have described two examples of this novel complication,
alopecia with fat atrophy, in a relatively small series of patients.
In light of this, we would suggest that all patients, especially
women, should be advised of this cosmetic side effect when con-
senting to the procedure. Moreover, it seems inadvisable in gen-
eral to inject the supraorbital nerve unless there is a specific
indication to do so.
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Middle interhemispheric variant of
holoprosencephaly: A very mild clinical case
R. Biancheri, MD; A. Rossi, MD; P. Tortori-Donati, MD;
S. Stringara, MSc; S. Bonifacino, MSc; and C. Minetti, MD
Middle interhemispheric variant (MIH) of holoprosencephaly or
syntelencephaly was described in 19931 as a fourth subtype of
holoprosencephaly (HPE), in addition to the three classic types of
alobar, semilobar, and lobar HPE.2 MIH consists of an abnormal
midline continuity of the posterior frontal and parietal regions of
the cerebral hemispheres, with separation of the basal forebrain,
anterior frontal lobes, and occipital regions. Although MIH and
classic HPE share a number of similarities, they are related to
different embryologic mechanisms. Classic HPE is caused by a
defect in the formation of the embryonic floor plate, whereas MIH
is secondary to a disturbance of formation of the roof plate.3 The
ZIC2 gene plays a critical role in differentiation of the roof plate of
the developing embryo in the dorsal midline of the neural tube.3 In
mice, decreased levels of ZIC2 result in the failure to form midline
CNS structures. In humans, mutations in the ZIC2 gene have
been found in ~3 to 4% of HPE cases, including individuals with
MIH, confirming that MIH is a variant of HPE.4
The clinical manifestations of MIH patients have been recently
reported in detail and compared with classic HPE.5 Neurologic
developmental functions were similar to the lobar subtype of HPE.
Figure. An example of alopecia with fat atrophy after lo-
cal injection of the area of the greater occipital nerve with
2% lidocaine and 160 mg methylprednisolone for
headache.
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In particular, speech and oromotor development were delayed in
all MIH cases; mild to moderate spasticity, hypotonia, and dysto-
nia occurred in a high percentage of cases, as did seizures. Facial
dysmorphisms were moderate or even mild. Severe midline
craniofacial anomalies, choreoathetosis, and endocrine dysfunc-
tion were absent in MIH cases.5
Case report. A 14-year-old boy was referred to us because of
muscular hypotonia and weakness. He is the first child of healthy,
nonconsanguineous parents. He was born at term after an un-
eventful pregnancy with normal delivery. Birth weight was 2,800
g. Motor development was slightly delayed (unsupported walking
acquired at age 18 months). He never had seizures. Despite the
presence of a mild reading disorder, his academic skills were
within the normal range.
Neurologic examination showed no facial dysmorphism
(namely, no hypotelorism or hypertelorism or single central max-
illary incisor), normal head circumference, mild weakness of eye
closure, a slightly reduced muscular tone and trophism, rigid
spine, proximal limb weakness mainly of the shoulders, and nor-
mal osteotendinous reflexes. He was able to walk independently
with lordosis. Cardiac and respiratory functions were apparently
normal. Endocrine functions and temperature regulation were
normal.
Laboratory investigations, including creatine kinase, transami-
nases, and karyotype, were normal. EKG was normal. EMG (del-
toid muscle) showed myogenic signs. Nerve conduction velocity
was normal. Muscle biopsy of quadriceps revealed only mild myo-
pathic changes, as increasing of the percentage of central nuclei
and type I fiber predominance, without specific degenerative or
inflammatory features.
IQ assessed with the Wechsler Intelligence Scale for Children–
Revised scale was normal (total IQ, 103; performance IQ, 101;
verbal IQ, 106).
Brain MRI revealed a middle interhemispheric variant of holo-
prosencephaly (figure).
Genetic analysis for sonic hedgehog was not performed. Re-
sults of mutational analysis for ZIC2 gene are not yet available.
Discussion. The severity of HPE correlates with the degree of
neurologic impairment and developmental delay. In the most se-
vere type (alobar), there is only a minimal developmental
progress, whereas the developmental outcome is more favorable in
milder forms of HPE (semilobar and lobar).6 Despite similarities
with lobar HPE, MIH represents a distinct cliniconeuroradiologic
subtype of HPE.5 The frequency of seizures, hypotonia, and dysto-
nia was comparable, whereas spasticity occurred more frequently
in MIH than in lobar HPE. Developmental neurologic abnormali-
ties, including mobility, upper extremity function, and expressive
language, were similar to those of lobar HPE. The degree of dys-
function of these variables has been correlated with the nonsepa-
ration of deep gray nuclei (caudate, lentiform nuclei, and
thalamus).6 Language development is poor in lobar HPE and MIH,
and patients are usually able to pronounce only single words or
short sentences.5,6
However, expressive language and intelligence of our case are
completely normal, and his academic skills are in the normal
range, except for a mild reading disability.
In conclusion, this case contributes to the further definition of
the phenotype of MIH, indicating that the clinical variability of
this disorder is wider than expected, also including a very mild
clinical phenotype.
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Figure. (A) Sagittal T1-weighted im-
age. (B–D) Coronal short tau inversion
recovery (STIR) images, anterior to pos-
terior. (A) Sagittal T1-weighted image
shows dysgenetic corpus callosum, with
a discernible genu (G) and splenium (S)
and a thin, central elongated commis-
sural structure (white arrows) whose
composition is difficult to ascertain. An-
teriorly, this structure is seen to con-
tinue below and above the callosal genu
(open arrow), whereas posteriorly it
merges with the undersurface of the cal-
losal splenium. (B) Coronal STIR im-
age at the level of the callosal genu
shows anterior pillars of the fornix
(white arrows), merging below the genu
to contribute to the commissure (open
arrow). (C) Coronal STIR image at an
intermediate level clearly shows a thin
sling of normal-appearing cortex bridg-
ing the midline just below the calloso-
marginal sulcus (arrowheads); note
that the cortex should never be found
between the commissural plate and the
callosomarginal sulcus in normal indi-
viduals. This bridging cortex represents
the site of uncleavage of the two cere-
bral hemispheres. At this level, the com-
missural structure is seen to connect the
hemispheric white matter of the two
cerebral hemispheres. (D) Coronal STIR image at the level of the callosal splenium shows the posterior pillars of the for-
nix (arrows) as they converge toward the undersurface of the splenium.
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story, or piece of creative nonfiction.
For information, visit http://aan.com/professionals/awards/award/awa_cre_exp.cfm.
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